Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
4.550
+0.020 (0.44%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Candel Therapeutics Employees
Candel Therapeutics had 38 employees as of December 31, 2024. The number of employees decreased by 4 or -9.52% compared to the previous year.
Employees
38
Change (1Y)
-4
Growth (1Y)
-9.52%
Revenue / Employee
n/a
Profits / Employee
-$1,452,026
Market Cap
215.87M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 38 | -4 | -9.52% |
Dec 31, 2023 | 42 | -34 | -44.74% |
Dec 31, 2022 | 76 | 11 | 16.92% |
Dec 31, 2021 | 65 | 24 | 58.54% |
Dec 31, 2020 | 41 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
CADL News
- 18 days ago - Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients - GlobeNewsWire
- 24 days ago - Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409 - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D. - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 7 weeks ago - Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data - Seeking Alpha
- 7 weeks ago - Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer - GlobeNewsWire
- 2 months ago - Candel Therapeutics: Entering Its Pivotal Year - Seeking Alpha